 鲜花( 85)  鸡蛋( 2)
|

楼主 |
发表于 2015-2-28 21:48
|
显示全部楼层
Stock soars after Cold-fX wins crucial approval5 z$ l1 F v% H/ _% ~$ J j
9 A7 |9 x- X# s5 h d" |; dEDMONTON - CV Technologies Inc. shares rose nearly 60 per cent Thursday after Health Canada approved the claims at the core of the company's marketing of its cold and flu drug Cold-fX.' ]7 p' ^6 H) F
, i3 T! T- j5 S! t- z# Z' B2 I
BY THE EDMONTON JOURNAL FEBRUARY 16, 2007# c- ^2 E0 J& H$ C
$ W; ?7 P0 {( a ) Y- Y+ W0 e9 g* N9 c/ ? p' M
EDMONTON - CV Technologies Inc. SHARES rose nearly 60 per cent Thursday after Health Canada approved the claims at the core of the company's marketing of its cold and flu drug Cold-fX.
5 `/ r4 R, W7 {4 P% |( B
$ N2 V3 R1 B# y# p. m2 d3 ZThe agency said CV Technologies can continue to market Cold-fX as helping "to reduce the frequency, severity and duration of cold and flu symptoms by boosting the IMMUNE SYSTEM."1 B7 [) Y( G7 U; D
6 s8 g6 U' R! d% w! o, S2 C" F. {The APPROVAL follows a review of seven clinical trials and more than 10 years of research about the product.
% S4 K+ B# S+ A& t: e5 p$ O; _2 i
k5 z+ v/ F: S! {2 B% X9 OIt should create even more confidence among consumers and medical professionals that the product works, CEO Jacqueline Shan said Thursday.
. P$ X7 q* w# ~4 G6 f* p6 O; H" l: F
It certainly instilled confidence in the market, as shares closed at $2.90 on THE TORONTO STOCK EXCHANGE, up $1.08 on a volume of 4.6 million.
/ n* `, n! U4 R1 J9 y& B
7 v. z* c& l: J, l0 n$ y) c"As a scientist, it's one of the highlights of my CAREER," Shan said.
; p, Z+ A+ s; R" p5 J. {% B2 ?) z% g a# G' |
"This approval is a breakthrough in realizing our vision of being a global leader in developing products for disease prevention."! w! N% J$ x" E0 B. k6 Q7 g% _
/ p! a, [% m" e6 }4 IIt's Cold-fX's strongest medical recognition to date, said Shan. It means the company can advertise the HEALTH BENEFITS more effectively to consumers and health professionals, she said.: `+ _( p! D7 x o8 s* r3 X
0 ^6 y' h% @5 S' H9 s% M2 C
Ginseng-based Cold-fX is already the top-selling cold and flu treatment in Canada, but Shan said there is plenty of room for more growth. S6 X5 J6 @( n/ h3 l+ a% l
, c- X; `' x1 `' \9 W+ Q
The approval will also help raise the product's PROFILE in the lucrative U.S. market, which Cold-fX entered in October. The move came with a new marketing push, using former Oilers superstar Mark Messier as its spokesman.
5 b4 B4 l3 U2 B: r8 C' U- @/ w& B" N5 N" {2 n
* m6 J! w2 N# U% T8 [& O4 N. ^( g
http://www.canada.com/story.html ... 9-be80-f40f1426f662 |
|